Clinical Trial: Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730125) titled 'Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies' on July 17.

Brief Summary: The goal of this Phase 1/2a observational study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer. The main questions it aims to answer are:

Phase 1

* Incidence of DLTs

* Incidence of CRG-150 related AEs and SAEs

* Select the Recommended Phase 2 Dose (RP2D), as determined through the dose escalation process for the specified indications Phase 2a

* HR+HER2- Breast Cancer and TNBC: Overall Response Rate...